Manufacturer of Controlled Substances; Notice of Registration, 61375 [E7-21311]
Download as PDF
<![CDATA[
sroberts on PROD1PC70 with NOTICES
Federal Register / Vol. 72, No. 209 / Tuesday, October 30, 2007 / Notices
entry of appearance with the Secretary
to the Commission, as provided in
sections 201.11 and 207.10 of the
Commission’s rules, not later than seven
days after publication of this notice in
the Federal Register. Industrial users
and (if the merchandise under
investigation is sold at the retail level)
representative consumer organizations
have the right to appear as parties in
Commission antidumping
investigations. The Secretary will
prepare a public service list containing
the names and addresses of all persons,
or their representatives, who are parties
to this investigation upon the expiration
of the period for filing entries of
appearance.
Limited disclosure of business
proprietary information (BPI) under an
administrative protective order (APO)
and BPI service list. Pursuant to section
207.7(a) of the Commission’s rules, the
Secretary will make BPI gathered in this
investigation available to authorized
applicants representing interested
parties (as defined in 19 U.S.C. 1677(9))
who are parties to the investigation
under the APO issued in the
investigation, provided that the
application is made not later than seven
days after the publication of this notice
in the Federal Register. A separate
service list will be maintained by the
Secretary for those parties authorized to
receive BPI under the APO.
Conference. The Commission’s
Director of Operations has scheduled a
conference in connection with this
investigation for 9:30 a.m. on November
13, 2007, at the U.S. International Trade
Commission Building, 500 E Street SW.,
Washington, DC. Parties wishing to
participate in the conference should
contact Fred Ruggles (202–205–3187/
fred.ruggles@usitc.gov) not later than
November 9, 2007, to arrange for their
appearance. Parties in support of the
imposition of antidumping duties in
this investigation and parties in
opposition to the imposition of such
duties will each be collectively
allocated one hour within which to
make an oral presentation at the
conference. A nonparty who has
testimony that may aid the
Commission’s deliberations may request
permission to present a short statement
at the conference.
Written submissions. As provided in
sections 201.8 and 207.15 of the
Commission’s rules, any person may
submit to the Commission on or before
November 16, 2007, a written brief
containing information and arguments
pertinent to the subject matter of the
investigation. Parties may file written
testimony in connection with their
presentation at the conference no later
VerDate Aug<31>2005
20:46 Oct 29, 2007
Jkt 214001
than three days before the conference. If
briefs or written testimony contain BPI,
they must conform with the
requirements of sections 201.6, 207.3,
and 207.7 of the Commission’s rules.
The Commission’s rules do not
authorize filing of submissions with the
Secretary by facsimile or electronic
means, except to the extent permitted by
section 201.8 of the Commission’s rules,
as amended, 67 FR 68036 (November 8,
2002). Even where electronic filing of a
document is permitted, certain
documents must also be filed in paper
form, as specified in II (C) of the
Commission’s Handbook on Electronic
Filing Procedures, 67 FR 68168, 68173
(November 8, 2002).
In accordance with sections 201.16(c)
and 207.3 of the rules, each document
filed by a party to the investigation must
be served on all other parties to the
investigation (as identified by either the
public or BPI service list), and a
certificate of service must be timely
filed. The Secretary will not accept a
document for filing without a certificate
of service.
Authority: This investigation is being
conducted under authority of title VII of the
Tariff Act of 1930; this notice is published
pursuant to section 207.12 of the
Commission’s rules.
Issued: October 25, 2007.
By order of the Commission.
Marilyn R. Abbott,
Secretary to the Commission.
[FR Doc. E7–21300 Filed 10–29–07; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated June 7, 2007, and
published in the Federal Register on
June 20, 2007, (72 FR 34039), Cambrex
Charles City, Inc., 1205 11th Street,
Charles City, Iowa 50616, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Lisdexamfetamine dimesylate (1205), a
basic class of controlled substance listed
in schedule II.
The company plans to manufacture
the listed controlled substance for sale
to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cambrex Charles City, Inc. to
manufacture the listed basic class of
controlled substance is consistent with
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
61375
the public interest at this time. DEA has
investigated Cambrex Charles City, Inc.
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with State
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: October 22, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–21311 Filed 10–29–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated June 7, 2007, and
published in the Federal Register on
June 20, 2007, (72 FR 34039), Cambrex
Charles City, Inc., 1205 11th Street,
Charles City, Iowa 50616, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Oxycodone (9143), a basic class of
controlled substance listed in schedule
II.
The company plans to manufacture
the listed controlled substance for sale
to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cambrex Charles City, Inc. to
manufacture the listed basic class of
controlled substance is consistent with
the public interest at this time. DEA has
investigated Cambrex Charles City, Inc.
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
E:\FR\FM\30OCN1.SGM
30OCN1
]]>Agencies
[Federal Register Volume 72, Number 209 (Tuesday, October 30, 2007)]
[Notices]
[Page 61375]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-21311]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated June 7, 2007, and published in the Federal Register
on June 20, 2007, (72 FR 34039), Cambrex Charles City, Inc., 1205 11th
Street, Charles City, Iowa 50616, made application by letter to the
Drug Enforcement Administration (DEA) to be registered as a bulk
manufacturer of Lisdexamfetamine dimesylate (1205), a basic class of
controlled substance listed in schedule II.
The company plans to manufacture the listed controlled substance
for sale to its customers.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Cambrex Charles City, Inc. to manufacture the listed basic class of
controlled substance is consistent with the public interest at this
time. DEA has investigated Cambrex Charles City, Inc. to ensure that
the company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with State and local laws, and a review of the company's background and
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with
21 CFR 1301.33, the above named company is granted registration as a
bulk manufacturer of the basic classes of controlled substances listed.
Dated: October 22, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E7-21311 Filed 10-29-07; 8:45 am]
BILLING CODE 4410-09-P
